Cargando…

Drug resistance in idiopathic generalized epilepsies: Evidence and concepts

Although approximately 10%–15% of patients with idiopathic generalized epilepsy (IGE)/genetic generalized epilepsy remain drug‐resistant, there is no consensus or established concept regarding the underlying mechanisms and prevalence. This review summarizes the recent data and the current hypotheses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gesche, Joanna, Beier, Christoph P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Critical Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092586/ https://www.ncbi.nlm.nih.gov/pubmed/36102351 http://dx.doi.org/10.1111/epi.17410

Ejemplares similares

Factors not considered in the study of drug‐resistant epilepsy: Drug‐resistant epilepsy: Assessment of neuroinflammation
por: Campos‐Bedolla, Patricia, et al.
Publicado: (2022)

The gut microbiome in drug‐resistant epilepsy
por: Chatzikonstantinou, Simela, et al.
Publicado: (2021)

Current Concepts in the Management of Idiopathic Generalized Epilepsies
por: Rathore, Chaturbhuj, et al.
Publicado: (2022)

Drug‐resistant epilepsy: Drug target hypothesis and beyond the receptors
por: Fonseca‐Barriendos, Daniel, et al.
Publicado: (2021)

The evolution of the concepts of seizures and epilepsy: What’s in a name?
por: Patel, Puja, et al.
Publicado: (2020)

Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
por: Rocha, Luisa, et al.
Publicado: (2020)

Introduction to the special issue “Redesigning the hypotheses for drug‐resistant epilepsy”
por: Rocha, Luisa
Publicado: (2022)

Drug‐resistant epilepsy and mortality—Why and when do neuromodulation and epilepsy surgery reduce overall mortality
por: Rheims, Sylvain, et al.
Publicado: (2022)

Factors not considered in the study of drug‐resistant epilepsy: Psychiatric comorbidities, age, and gender
por: Medel‐Matus, Jesús Servando, et al.
Publicado: (2022)

Drug‐resistant epilepsy and the hypothesis of intrinsic severity: What about the high‐frequency oscillations?
por: Santana‐Gomez, Cesar E., et al.
Publicado: (2021)

The role of efflux transporters and metabolizing enzymes in brain and peripheral organs to explain drug‐resistant epilepsy
por: Vázquez, Marta, et al.
Publicado: (2021)

Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy
por: Perucca, Emilio, et al.
Publicado: (2016)

Management of post‐traumatic epilepsy: An evidence review over the last 5 years and future directions
por: Piccenna, Loretta, et al.
Publicado: (2017)

Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy
por: Galanopoulou, Aristea S., et al.
Publicado: (2016)

Acetazolamide: Old drug, new evidence?
por: Shukralla, Arif Ali, et al.
Publicado: (2022)

Structure and function of language networks in temporal lobe epilepsy
por: Binding, Lawrence P., et al.
Publicado: (2022)

The right and the wrong with epilepsy and her science
por: Shorvon, Simon, et al.
Publicado: (2016)

Epilepsy in Morocco: Realities, pitfalls and prospects
por: Kissani, Najib, et al.
Publicado: (2020)

Status of epilepsy in the tropics: An overlooked perspective
por: Liu, Jiaqi, et al.
Publicado: (2023)

Epilepsy in Niger: An overview of the current situation
por: Toudou‐Daouda, Moussa
Publicado: (2023)

Choice of Antiepileptic Drugs in Idiopathic Generalized Epilepsy: UAE Experience
por: Alsaadi, Taoufik, et al.
Publicado: (2015)

Serotonin receptors in epilepsy: Novel treatment targets?
por: Sourbron, Jo, et al.
Publicado: (2022)

Climate change and epilepsy: Time to take action
por: Sisodiya, Sanjay M., et al.
Publicado: (2019)

Wearable OPM‐MEG: A changing landscape for epilepsy
por: Pedersen, Mangor, et al.
Publicado: (2022)

Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders
por: Katsarou, Anna‐Maria, et al.
Publicado: (2017)

Neurodegenerative pathways as targets for acquired epilepsy therapy development
por: Casillas‐Espinosa, Pablo M., et al.
Publicado: (2020)

Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?
por: Czornyj, Liliana, et al.
Publicado: (2021)

Statins as antiepileptogenic drugs: Analyzing the evidence and identifying the most promising statin
por: Hufthy, Yousif, et al.
Publicado: (2022)

A complex systems view on the current hypotheses of epilepsy pharmacoresistance
por: Servilha‐Menezes, Gabriel, et al.
Publicado: (2022)

The enigmatic figure of Leon Pierce Clark and his contribution to epilepsy
por: Shorvon, Simon D.
Publicado: (2022)

Not all that glitters is gold: A guide to surgical trials in epilepsy
por: Jehi, Lara, et al.
Publicado: (2016)

Sudden unexpected death in epilepsy: A critical view of the literature
por: Giussani, Giorgia, et al.
Publicado: (2023)

Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations
por: Schmitz, Bettina, et al.
Publicado: (2023)

Neurovascular unit dysfunction as a mechanism of seizures and epilepsy during aging
por: van Vliet, Erwin A., et al.
Publicado: (2022)

The initial impact of the SARS‐CoV‐2 pandemic on epilepsy research
por: Volkers, Nancy, et al.
Publicado: (2021)

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
por: Bonilla, Lorena, et al.
Publicado: (2021)

Transforming epilepsy research: A systematic review on natural language processing applications
por: Yew, Arister N. J., et al.
Publicado: (2022)

The Prognosis and Treatment of Epilepsy
por: Parkes, E. A.
Publicado: (1853)

Mental Maladies and Epilepsy
Publicado: (1877)

Cerebral Physiology and Epilepsy
Publicado: (1877)

Cannot write session to /tmp/vufind_sessions/sess_hoeeavkda25jij42pmpft9eh28